Summary of Key Points Core Viewpoint - The company intends to temporarily use part of its idle raised funds to supplement working capital, ensuring that this does not affect the implementation of its fundraising investment projects [1][4][6]. Group 1: Fundraising Overview - The company raised a total of RMB 894,999,954.16, with a net amount of RMB 875,792,998.29 after deducting related expenses [1][2]. - The funds were raised through the issuance of 96,030,038 shares at a price of RMB 9.32 per share, approved by the China Securities Regulatory Commission on June 26, 2023 [1]. Group 2: Fund Management and Usage - The company has established a fundraising supervision account and signed a tripartite/four-party supervision agreement with the sponsor and relevant banks [2]. - As of July 1, 2025, the company has used RMB 69,363.46 million of the raised funds, leaving RMB 18,985.96 million (including interest and net cash management income) unutilized [2]. Group 3: Temporary Fund Usage - The company plans to use up to RMB 17,500 million of idle funds to temporarily supplement working capital, with a usage period of up to 12 months from the board's approval [4][5]. - This temporary use of funds is expected to save approximately RMB 5.25 million in financial costs based on the current one-year loan market quotation rate of 3% [4]. Group 4: Compliance and Approval - The board and supervisory committee have approved the use of idle funds, confirming that it will not affect the normal progress of fundraising investment projects [6]. - The sponsor has verified that the company's actions comply with relevant regulations and do not change the intended use of the raised funds [6].

海南金盘智能科技股份有限公司 第一章 总 则 公司发现控股股东、实际控制人及其他关联人占用募集资金的，应当及时要 求归还，并披露占用发生的原因、对公司的影响、清偿整改方案及整改进展情况。 公司的董事和高级管理人员应当勤勉尽责，确保公司募集资金安全，不得操 控公司擅自或者变相改变募集资金用途。 第二章 募集资金存储 第四条 公司应当审慎选择商业银行并开设募集资金专项账户（以下简称 "募集资金专户"），募集资金应当存放于经董事会批准设立的募集资金专户集 中管理和使用。募集资金专户不得存放非募集资金或者用作其它用途。 公司存在两次以上融资的，应当分别设置募集资金专户。超募资金也应当存 放于募集资金专户管理。 第五条 公司应当在募集资金到账后一个月内与保荐机构或者独立财务顾 问、存放募集资金的商业银行（以下简称"商业银行"）签订募集资金专户存储 三方监管协议并及时公告。相关协议签订后，公司可以使用募集资金。该协议至 少应当包括以下内容： 第一条 为规范海南金盘智能科技股份有限公司（以下简称"公司"）募集 资金的使用与管理，提高募集资金的使用效率，防范资金使用风险，确保资金使 用安全，保护投资者的利益，根据《中华人民共 ...

天赐材料（002709） 广州天赐高新材料股份有限公司 （H 股发行并上市后适用） 第一章 总 则 第一条 为规范广州天赐高新材料股份有限公司（以下简称"公司"）募集 资金的管理和使用，提高募集资金使用效益，保护投资者利益，根据《中华人 民共和国公司法》《中华人民共和国证券法》《上市公司证券发行注册管理办 法》《上市公司募集资金监管规则》《深圳证券交易所股票上市规则》《深圳证券 交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《香港联合交 易所有限公司证券上市规则》（以下简称"《香港上市规则》"）等法律、行政法 规、规范性文件、公司股票上市地证券监管规则及《广州天赐高新材料股份有 限公司章程》（以下简称"《公司章程》"），并结合本公司实际，特制定本制度。 第二条 本制度所称募集资金是指公司通过发行股票或者其他具有股权性 质的证券，向投资者募集并用于特定用途的资金，但不包括公司为实施股权激 励计划募集的资金。 本公司在境内公开发行证券以及定向发行证券的募集资金管理适用本制度 的相关规定。 公司在香港证券市场通过发行 H 股募集资金管理按照《香港上市规则》及 公司其他内部管理制度的相关规定执行。 本 ...

Group 1 - The company held its 21st meeting of the 3rd Supervisory Board on July 4, 2025, in Huizhou, with all procedures complying with relevant laws and regulations [1] - The Supervisory Board unanimously approved the correction of accounting errors and the revision of periodic reports, ensuring that the financial data accurately reflects the company's financial status and operational results [1] - The meeting was attended by three supervisors, and the voting results showed 3 votes in favor, with no opposition or abstentions [2] Group 2 - The Supervisory Board agreed that using self-owned funds to pay for fundraising project expenses and replacing them with equivalent raised funds would enhance the efficiency of fund usage [2] - The implementation of this matter will not affect the normal progress of fundraising projects and does not violate any regulations regarding the use of raised funds [2] - The voting results for this proposal also showed 3 votes in favor, with no opposition or abstentions [2]

民生证券股份有限公司 关于深圳市信宇人科技股份有限公司 使用自有资金支付募投项目所需资金并以募集资金等额置换 的核查意见 根据公司披露的《首次公开发行股票并在科创板上市招股说明书》及《关于 变更部分募投项目实施方式及地点、调整内部投资结构暨追加投资并延期的公告 》（公告编号：2025-012），公司募集资金使用计划如下： | | | | 单位：万元 | | --- | --- | --- | --- | | 序号 | 募投项目 | 投资总额 | 募集资金投入金额 | | | 合计 | 61,851.60 | 46,224.66 | | | 三、使用自有资金支付募投项目所需资金并以募集资金等额置换的原因 | | | 根据募集资金专款专用原则，募集资金到位后相关支出原则上均应从募集资 金专户直接支付划转。在募投项目的实施过程中，基于实际情况，公司存在以自 有资金先行支付募投项目的部分款项，后续再由募集资金专户等额划转资金至公 司基本存款账户或一般存款账户进行置换的实际需求，具体原因如下： 公司募投项目在实施过程中需要支付土地购买费用。根据税务机关的要求， 公司的土地费用的缴纳需通过公司在税务系统绑定的账户进行支付 ...

Group 1 - The company is holding its second extraordinary general meeting of shareholders in 2025 to discuss key proposals, including stock issuance and dividend plans [1][2][8] - The meeting will take place on July 16, 2025, at 15:00, with both on-site and online voting options available [7][5] - The company emphasizes the importance of maintaining order and protecting shareholder rights during the meeting [2][3] Group 2 - Proposal one involves issuing stocks through a simplified procedure, with a focus on the potential dilution of immediate returns for existing shareholders and measures to compensate for this dilution [6][8] - Proposal two outlines the company's dividend return plan for the next three years (2025-2027), aimed at enhancing transparency and operational feasibility in profit distribution [8][9] - Proposal three presents a report on the usage of previously raised funds, which has been verified by an accounting firm [9][10]

Group 1 - The company is proposing a stock option incentive plan for 2025 to attract and retain talent, aligning the interests of shareholders, the company, and core team members [5][6][8] - The stock option incentive plan has been approved by the company's board and supervisory committee and is now submitted for shareholder approval [6][8] - The company will conduct the shareholder meeting on July 14, 2025, with both on-site and online voting options available [5][7] Group 2 - The company plans to change its name from "Jiangsu Aidea Pharmaceutical Co., Ltd." to "Jiangsu Aidea Pharmaceutical Group Co., Ltd." to enhance group management and resource utilization [12][13] - The name change aligns with the company's strategic development needs and will not adversely affect its operations or shareholder interests [13][14] - The company will also revise its articles of association to reflect the name change and will seek necessary approvals for the changes [14][22] Group 3 - The company intends to adjust its fundraising investment projects, specifically changing the focus from "Ustectidine New Indication Research Project" to "Integrase Inhibitor Drug Research and Clinical Study Project" [16][19] - The total amount of funds to be redirected is approximately 84.37 million yuan, which will be fully allocated to the new project [15][19] - The integrase inhibitor project aims to develop a new generation of anti-HIV drugs and has shown promising results in initial clinical trials [20][21] Group 4 - The company is proposing the appointment of a new independent director candidate, Hu Wenyuan, following the resignation of the previous independent director [11][12] - The nomination has been approved by the board and is now subject to shareholder approval [11][12] - The company is also seeking to fill a vacancy in the supervisory board due to the resignation of a non-employee representative supervisor [22][23]

Core Viewpoint - The announcement details the usage of previously raised funds by Wangli Security Technology Co., Ltd., confirming that all funds have been utilized as planned without any changes to investment projects or idle funds remaining [1][4][6]. Fundraising Details - The company raised a total of RMB 69,144.00 million by issuing 67 million shares at RMB 10.32 per share, with a net amount of RMB 59,850.65 million after deducting fees [1]. - The funds were verified by Tianjian Accounting Firm, which issued a verification report [1]. Fund Storage Situation - As of December 31, 2024, the total amount of funds in the bank accounts was RMB 63,858.20 million, all of which have been closed [2][3]. Actual Usage of Funds - The total amount of funds actually used was RMB 60,272.19 million, which includes investments in a new production base for smart home products and working capital [5][6]. Changes in Investment Projects - There were no changes to the investment projects funded by the raised capital [4]. Temporary Idle Funds - The company approved the use of up to RMB 200 million of temporarily idle funds for cash management, ensuring that it would not affect the construction of investment projects or normal operations [4]. Remaining Funds - As of December 31, 2024, there were no remaining funds, and the fundraising account has been canceled [4]. Project Performance - The investment projects have achieved a total benefit of RMB 14,975.58 million, with an expected benefit realization rate of 84.35%, primarily affected by the downturn in the real estate sector and increased expenses [7].

Core Points - The document outlines the fundraising management system of Chengdu Yunda Technology Co., Ltd, aiming to regulate the management and usage of raised funds to enhance efficiency [1] - The company is required to strictly manage and disclose the usage of raised funds in accordance with relevant laws and regulations [1][4] - The board of directors is responsible for establishing and ensuring the effective implementation of the fundraising management system [1][4] Fundraising Management - The company must open a special account for raised funds, ensuring that these funds are not mixed with other funds or used for unrelated purposes [2][5] - A tripartite supervision agreement must be signed with the sponsor or independent financial advisor and the commercial bank within one month of the funds being received [2][3] - The company is prohibited from changing the purpose of the raised funds without proper approval and must disclose the actual usage of the funds accurately [4][5] Fund Usage - Raised funds must be used in accordance with the commitments made in the prospectus, and any significant changes must be disclosed [4][6] - The company must ensure that raised funds are not used for high-risk investments or for the benefit of related parties [4][5] - If funds are found to be misappropriated by controlling shareholders or related parties, the company must take action to recover the funds and disclose the situation [5][6] Fund Management and Supervision - The board must continuously monitor the actual storage, management, and usage of the raised funds, providing semi-annual reports [25][26] - Any discrepancies between the actual investment progress and the planned investment must be explained, and adjustments to the investment plan must be disclosed [13][26] - Independent financial advisors must conduct regular checks on the management of raised funds and report any irregularities to the Shenzhen Stock Exchange [14][15]

证券代码：603079 证券简称：圣达生物 公告编号：2025-030 浙江圣达生物药业股份有限公司 第四届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 浙江圣达生物药业股份有限公司（以下简称"公司"）第四届监事会第十 六次会议（以下简称"本次会议"）于2025年7月7日在公司会议室以现场表决 方式召开。本次会议已于2025年7月4日以电子邮件结合短信方式通知全体监事。 本次会议由公司监事会主席徐涵先生主持，应到监事3人，实到监事3人。 本次会议的通知、召开、表决程序符合《中华人民共和国公司法》等法 律、行政法规、部门规章、规范性文件及《浙江圣达生物药业股份有限公司章 程》的有关规定，会议形成的决议合法有效。 二、监事会会议审议情况 （二）审议通过《关于使用募集资金向控股子公司提供借款用于实施募投 项目的议案》 具体内容详见公司同日刊载于《上海证券报》、《证券时报》及上海证券 交易所网站（www.sse.com.cn）的《浙江圣达生物药业股份有限公司关于使用 募集资金向控股 ...